Oral lichenoid tissue reactions: Diagnosis and classification

Expert Review of Molecular Diagnostics

Volumn 14, Issue 2, 2014, Pages 169-184

  Khudhur, Ahmed Salih ^a   Di Zenzo, Giovanni ^b   Carrozzo, Marco ^a,c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

chronic ulcerative stomatitis; discoid lupus erythematosus; erythema multiforme; graft versus host disease; lichen planus; lichen planus pemphigoid; lichenoid lesions; oral lichen planus; paraneoplastic pemphigus paraneoplastic autoimmune multiorgan syndrome; systemic lupus erythematosus

Indexed keywords

DENTAL RESTORATION, PERMANENT; DERMATOLOGY; ERYTHEMA MULTIFORME; GINGIVITIS, NECROTIZING ULCERATIVE; GRAFT VS HOST DISEASE; HUMANS; LICHEN PLANUS, ORAL; LICHENOID ERUPTIONS; LUPUS ERYTHEMATOSUS, DISCOID; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOUTH MUCOSA; PEMPHIGOID, BULLOUS; PEMPHIGUS;

EID: 84894597034     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2014.888953     Document Type: Review

References (139)

1. Pinkus H. Lichenoid tissue reactions. A speculative review of the clinical spectrum of epidermal basal cell damage with special reference to erythema dyschromicum perstans. Arch Dermatol 1973;107(6):840-6
2. Sontheimer RD. Lichenoid tissue reaction/ interface dermatitis: clinical and histological perspectives. J Invest Dermatol 2009;129(5): 1088-99
3. Schlosser BJ. Lichen planus and lichenoid reactions of the oral mucosa. Dermatol Ther 2010;23(3):251-67
4. Al-Hashimi I, Schifter M, Lockhart PB, et al. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103(Suppl):S25.e21-12
5. Cortes-Ramirez DA, Gainza-Cirauqui ML, Echebarria-Goikouria MA, Aguirre-Urizar JM. Oral lichenoid disease as a premalignant condition: the controversies and the unknown. Med Oral Patol Oral Cir Bucal 2009;14(3):E118-22
6. Ismail SB, Kumar SK, Zain RB. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci 2007;49(2):89-106
7. van der Meij EH, van der Waal I. Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications. J Oral Pathol Med 2003; 32(9):507-12
8. Carrozzo M, Thorpe R. Oral lichen planus: a review. Minerva Stomatol 2009;58(10): 519-37
9. Aguirre Urizar JM. Letter to the editor: oral lichenoid disease. A new classification proposal. Med Oral Patol Oral Cir Bucal 2008;13(4):E224
10. van der Waal I. Oral lichen planus and oral lichenoid lesions; a critical appraisal with emphasis on the diagnostic aspects. Med Oral Patol Oral Cir Bucal 2009;14(7): E310-14
11. Scully C, Carrozzo M. Oral mucosal disease: lichen planus. Br J Oral Maxillofac Surg 2008;46(1):15-21
12. Eisen D, Carrozzo M, Bagan Sebastian JV, Thongprasom K. Number V Oral lichen planus: clinical features and management. Oral Dis 2005;11(6):338-49
13. Rodstrom PO, Jontell M, Mattsson U, Holmberg E. Cancer and oral lichen planus in a Swedish population. Oral Oncol 2004; 40(2):131-8
14. Carrozzo M, Uboldi de Capei M, Dametto E, et al. Tumor necrosis factor-alpha and interferon-gamma polymorphisms contribute to susceptibility to oral lichen planus. J Invest Dermatol 2004;122(1):87-94
15. Jin X, Wang J, Zhu L, et al. Association between -308 G/A polymorphism in TNF-alpha gene and lichen planus: a meta-analysis. J Dermatol Sci 2012;68(3): 127-34
16. Thornhill MH, Pemberton MN, Simmons RK, Theaker ED. Amalgam-contact hypersensitivity lesions and oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95(3): 291-9
17. Shengyuan L, Songpo Y, Wen W, et al. Hepatitis C virus and lichen planus: a reciprocal association determined by a meta-analysis. Arch Dermatol 2009;145(9): 1040-7
18. Lodi G, Pellicano R, Carrozzo M. Hepatitis C virus infection and lichen planus: a systematic review with meta-analysis. Oral Dis 2010;16(7):601-12
19. Petti S, Rabiei M, De Luca M, Scully C. The magnitude of the association between hepatitis C virus infection and oral lichen planus: meta-analysis and case control study. Odontology 2011;99(2):168-78
20. Pilli M, Penna A, Zerbini A, et al. Oral lichen planus pathogenesis: a role for the HCV-specific cellular immune response. Hepatology 2002;36(6):1446-52
21. Holmstrup P, Thorn JJ, Rindum J, Pindborg JJ. Malignant development of lichen planus-affected oral mucosa. J Oral Pathol 1988;17(5):219-25
22. Gandolfo S, Richiardi L, Carrozzo M, et al. Risk of oral squamous cell carcinoma in 402 patients with oral lichen planus: a follow-up study in an Italian population. Oral Oncol 2004;40(1):77-83
23. Helander SD, Rogers RS 3rd. The sensitivity and specificity of direct immunofluorescence testing in disorders of mucous membranes. J Am Acad Dermatol 1994;30(1):65-75
24. Calabresi V, Carrozzo M, Cozzani E, et al. Oral pemphigoid autoantibodies preferentially target BP180 ectodomain. Clin Immunol 2007;122(2):207-13
25. Carrozzo M. A reappraisal of diagnostic criteria for mucous membrane pemphigoid. J Oral Pathol Med 2009;38(1):160
26. Buijsrogge JJ, Hagel C, Duske U, et al. IgG antibodies to BP180 in a subset of oral lichen planus patients. J Dermatol Sci 2007; 47(3):256-8
27. Baccaglini L, Thongprasom K, Carrozzo M, Bigby M. Urban legends series: lichen planus. Oral Dis 2013;19(2):128-43
28. McParland H, Warnakulasuriya S. Oral lichenoid contact lesions to mercury and dental amalgam - a review. J Biomed Biotechnol 2012;2012:589569
29. Jensen SJ. Maximum contents of mercury in dental silver amalgams. Scand J Dent Res 1985;93(1):84-8
30. Dunsche A, Frank MP, Luttges J, et al. Lichenoid reactions of murine mucosa associated with amalgam. Br J Dermatol 2003;148(4):741-8
31. Seno K, Ohno J, Ota N, et al. Lupus-like oral mucosal lesions in mercury-induced autoimmune response in Brown Norway rats. BMC Immunol 2013;14:47
32. Holmstrup P. Reactions of the oral mucosa related to silver amalgam: a review. J Oral Pathol Med 1991;20(1):1-7
33. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 1997;27(2):175-81
34. von Blomberg-van der Flier M, van der Burg CK, Pos O, et al. In vitro studies in nickel allergy: diagnostic value of a dual parameter analysis. J Invest Dermatol 1987;88(4):362-8
35. Cederbrant K, Gunnarsson LG, Hultman P, et al. In vitro lymphoproliferative assays with HgCl2 cannot identify patients with systemic symptoms attributed to dental amalgam. J Dent Res 1999;78(8):1450-8
36. McCartan BE, McCreary CE. Oral lichenoid drug eruptions. Oral Dis 1997; 3(2):58-63
37. Thompson DF, Skaehill PA. Drug-induced lichen planus. Pharmacotherapy 1994;14(5): 561-71
38. Lamey PJ, McCartan BE, MacDonald DG, MacKie RM. Basal cell cytoplasmic autoantibodies in oral lichenoid reactions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;79(1):44-9
39. Van den Haute V, Antoine JL, Lachapelle JM. Histopathological discriminant criteria between lichenoid drug eruption and idiopathic lichen planus: retrospective study on selected samples. Dermatologica 1989;179(1):10-13
40. McCartan BE, Lamey P. Lichen planus - specific antigen in oral lichen planus and oral lichenoid drug eruptions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;89(5):585-7
41. Dickinson AM, Sviland L, Wang XN, et al. Predicting graft-versus-host disease in HLA-identical bone marrow transplant: a comparison of T-cell frequency analysis and a human skin explant model. Transplantation 1998;66(7):857-63
42. Wang XN, Collin M, Sviland L, et al. Skin explant model of human graft-versus-host disease: prediction of clinical outcome and correlation with biological risk factors. Biol Blood Marrow Transplant 2006;12(2): 152-9
43. Imanguli MM, Alevizos I, Brown R, et al. Oral graft-versus-host disease. Oral Dis 2008;14(5):396-412
44. Filipovich AH. Diagnosis and manifestations of chronic graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21(2):251-7
45. Woo SB, Lee SJ, Schubert MM. Graft-vs.- host disease. Crit Rev Oral Biol Med 1997; 8(2):201-16
46. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990;323(25): 1729-35
47. Nguyen VT, Ndoye A, Bassler KD, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol 2001;137(2):193-206
48. Nikolskaia OV, Nousari CH, Anhalt GJ. Paraneoplastic pemphigus in association with Castleman's disease. Br J Dermatol 2003;149(6):1143-51
49. Schepens I, Jaunin F, Begre N, et al. The protease inhibitor alpha-2-macroglobulinlike-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. PLoS One 2010;5(8):e12250
50. Martel P, Loiseau P, Joly P, et al. Paraneoplastic pemphigus is associated with the DRB1*03 allele. J Autoimmun 2003; 20(1):91-5
51. Liu Q, Bu DF, Li D, Zhu XJ. Genotyping of HLA-I and HLA-II alleles in Chinese patients with paraneoplastic pemphigus. Br J Dermatol 2008;158(3):587-91
52. Liu AY, Valenzuela R, Helm TN, et al. Indirect immunofluorescence on rat bladder transitional epithelium: a test with high specificity for paraneoplastic pemphigus. J Am Acad Dermatol 1993;28(5 Pt 1): 696-9
53. Helou J, Allbritton J, Anhalt GJ. Accuracy of indirect immunofluorescence testing in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol 1995;32(3):441-7
54. Probst C, Schlumberger W, Stocker W, et al. Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Clin Chim Acta 2009;410(1-2):13-18
55. Poot AM, Diercks GF, Kramer D, et al. Laboratory diagnosis of paraneoplastic pemphigus. Br J Dermatol 2013;169(5): 1016-24
56. Nieboer C. The reliability of immunofluorescence and histopathology in the diagnosis of discoid lupus erythematosus and lichen planus. Br J Dermatol 1987; 116(2):189-98
57. Nagao K, Chen KR. A case of lupus erythematosus/lichen planus overlap syndrome. J Dermatol 2006;33(3):187-90
58. Oke V, Wahren-Herlenius M. Cutaneous lupus erythematosus: clinical aspects and molecular pathogenesis. J Intern Med 2013; 273(6):544-54
59. Jarvinen TM, Hellquist A, Koskenmies S, et al. Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus. Exp Dermatol 2010;19(2):123-31
60. Jarvinen TM, Hellquist A, Koskenmies S, et al. Polymorphisms of the ITGAM gene confer higher risk of discoid cutaneous than of systemic lupus erythematosus. PLoS One 2010;5(12):e14212
61. Namjou B, Kothari PH, Kelly JA, et al. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun 2011;12(4):270-9
62. Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2009;4: Cd002954
63. Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 2009;10(6): 365-81
64. Callen JP. Cutaneous lupus erythematosus: a personal approach to management. Australas J Dermatol 2006;47(1):13-27
65. Merola JF, Prystowsky SD, Iversen C, et al. Association of discoid lupus erythematosus with other clinical manifestations among patients with systemic lupus erythematosus. J Am Acad Dermatol 2013;69(1):19-24
66. Uva L, Miguel D, Pinheiro C, et al. Cutaneous manifestations of systemic lupus erythematosus. Autoimmune Dis 2012;2012:834291
67. Werth VP. Clinical manifestations of cutaneous lupus erythematosus. Autoimmun Rev 2005;4(5):296-302
68. Thorne JE, Jabs DA, Nikolskaia O, et al. Discoid lupus erythematosus and cicatrizing conjunctivitis: clinicopathologic study of two cases. Ocul Immunol Inflamm 2002; 10(4):287-92
69. Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol 2006;24(5):348-62
70. Chong BF, Song J, Olsen NJ. Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. Br J Dermatol 2012;166(1): 29-35
71. Nico MM, Vilela MA, Rivitti EA, Lourenco SV. Oral lesions in lupus erythematosus: correlation with cutaneous lesions. Eur J Dermatol 2008;18(4):376-81
72. Tao D, Shangwu L, Yan L, et al. Retraction: CD226 expression deficiency causes high sensitivity to apoptosis in NK T cells from patients with systemic lupus erythematosus. J Immunol 2012;188(11): 5800
73. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25(11):1271-7
74. Lee JS, Haug BL, Sibley JT. Decreased mRNA levels coding for poly(ADP-ribose) polymerase in lymphocytes of patients with SLE. Lupus 1994;3(2):113-16
75. Chong BF, Tseng LC, Lee T, et al. IgG and IgM autoantibody differences in discoid and systemic lupus patients. J Invest Dermatol 2012;132(12):2770-9
76. Hung T, Ian Crawford R, Martinka M. Degree of histologic inflammation in lupus erythematosus and direct immunofluorescence results: red and inflamed lesions do not increase the chances of getting a bright band. J Cutan Med Surg 2013;17(1):22-6
77. Harley IT, Kaufman KM, Langefeld CD, et al. Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat Rev Genet 2009;10(5):285-90
78. Fernando MM, Stevens CR, Sabeti PC, et al. Identification of two independent risk factors for lupus within the MHC in United Kingdom families. PLoS Genet 2007;3(11):e192
79. Harley JB, Alarcon-Riquelme ME, Criswell LA, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008;40(2):204-10
80. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum 1999;42(9):1785-96
81. Jonsson R, Heyden G, Westberg NG, Nyberg G. Oral mucosal lesions in systemic lupus erythematosus - a clinical, histopathological and immunopathological study. J Rheumatol 1984;11(1):38-42
82. Jorizzo JL, Salisbury PL, Rogers RS 3rd, et al. Oral lesions in systemic lupus erythematosus. Do ulcerative lesions represent a necrotizing vasculitis? J Am Acad Dermatol 1992;27(3):389-94
83. McCauliffe DP. Cutaneous lupus erythematosus. Semin Cutan Med Surg 2001;20(1):14-26
84. Fritzler MJ. Toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent. Autoimmunity Highlights 2012;3(2):51-8
85. Licarete E, Ganz S, Recknagel MJ, et al. Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseases. BMC Immunol 2012;13:16
86. Jaremko WM, Beutner EH, Kumar V, et al. Chronic ulcerative stomatitis associated with a specific immunologic marker. J Am Acad Dermatol 1990;22(2 Pt 1):215-20
87. Worle B, Wollenberg A, Schaller M, et al. Chronic ulcerative stomatitis. Br J Dermatol 1997;137(2):262-5
88. Chorzelski TP, Olszewska M, Jarzabek-Chorzelska M, Jablonska S. Is chronic ulcerative stomatitis an entity? Clinical and immunological findings in 18 cases. Eur J Dermatol 1998;8(4):261-5
89. Solomon LW, Aguirre A, Neiders M, et al. Chronic ulcerative stomatitis: clinical, histopathologic, and immunopathologic findings. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;96(6):718-26
90. Islam MN, Cohen DM, Ojha J, et al. Chronic ulcerative stomatitis: diagnostic and management challenges - four new cases and review of literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104(2):194-203
91. Solomon LW. Chronic ulcerative stomatitis. Oral Dis 2008;14(5):383-9
92. Cozzani E, Cacciapuoti M, di Marco E, et al. Patients with oral erosive and cutaneous lichen planus may have antibodies directed against the chronic ulcerative stomatitis protein antigen of 70-kDa. Acta Dermatovenerol Alp Panonica Adriat 2008;17(3):120-4
93. Solomon LW, Stark PC, Winter L, et al. ELISA test for p63 antibodies in chronic ulcerative stomatitis. Oral Dis 2010;16(2): 151-5
94. Carlson MW, Garlick JA, Solomon LW. Chronic ulcerative stomatitis: evidence of autoimmune pathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 111(6):742-8
95. Fourie J, van Heerden WF, McEachen SC, van Zyl A. Chronic ulcerative stomatitis: a distinct clinical entity? SADJ 2011;66(3): 119-21
96. Rinaggio J, Crossland DM, Zeid MY. A determination of the range of oral conditions submitted for microscopic and direct immunofluorescence analysis. J Periodontol 2007;78(10):1904-10
97. Parodi A, Cozzani E, Chorzelski TP, et al. A molecule of about 70 kd is the immunologic marker of chronic ulcerative stomatitis. J Am Acad Dermatol 1998; 38(6 Pt 1):1005-6
98. Vassileva S. Drug-induced pemphigoid: bullous and cicatricial. Clin Dermatol 1998; 16(3):379-87
99. Carrizosa AM, Elorza FL, Camacho FM. Antinuclear antibodies in patients with lichen planus. Exp Dermatol 1997;6(1):54-6
100. Cacciapuoti M, Di Marco E, Cozzani E, et al. The antibody to the 70-kd antigen in chronic ulcerative stomatitis and lichen planus. J Am Acad Dermatol 2004;50(3): 486
101. Parodi A, Cozzani E, Massone C, et al. Prevalence of stratified epithelium-specific antinuclear antibodies in 138 patients with lichen planus. J Am Acad Dermatol 2007; 56(6):974-8
102. Lee LA, Walsh P, Prater CA, et al. Characterization of an autoantigen associated with chronic ulcerative stomatitis: the CUSP autoantigen is a member of the p53 family. J Invest Dermatol 1999;113(2): 146-51
103. Choi HR, Batsakis JG, Zhan F, et al. Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum Pathol 2002; 33(2):158-64
104. Solomon LW, Helm TN, Stevens C, et al. Clinical and immunopathologic findings in oral lichen planus pemphigoides. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103(6):808-13
105. Ebrahimi M, Nylander E, Backlund B, et al. The use of a novel ELISA method for detection of antibodies against p63 in sera from patients diagnosed with oral and/or genital and skin lichen planus. J Oral Pathol Med 2010;39(6):486-90
106. Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 2011;7(6):803-13.quiz 814-805
107. Carrozzo M, Togliatto M, Gandolfo S. [Erythema multiforme. A heterogeneous pathologic phenotype]. Minerva Stomatol 1999;48(5):217-26
108. Dumas V, Thieulent N, Souillet AL, et al. Recurrent erythema multiforme and chronic hepatitis C: efficacy of interferon alpha. Br J Dermatol 2000;142(6):1248-9
109. Ozkaya E. Oral mucosal fixed drug eruption: characteristics and differential diagnosis. J Am Acad Dermatol 2013;69(2): e51-8
110. Webster K, Godbold P. Nicorandil induced oral ulceration. Br Dent J 2005;198(10): 619-21
111. Oyama N, Setterfield JF, Gratian MJ, et al. Oral and genital lichenoid reactions associated with circulating autoantibodies to desmoplakins I and II: a novel target antigen or example of epitope spreading? J Am Acad Dermatol 2003;48(3):433-8
112. Farthing P, Bagan JV, Scully C. Mucosal disease series. Number IV. Erythema multiforme. Oral Dis 2005;11(5):261-7
113. Scully C, Bagan J. Oral mucosal diseases: erythema multiforme. Br J Oral Maxillofac Surg 2008;46(2):90-5
114. Williams PM, Conklin RJ. Erythema multiforme: a review and contrast from Stevens-Johnson syndrome/toxic epidermal necrolysis. Dent Clin North Am 2005; 49(1):67-76.viii
115. Khalil I, Lepage V, Douay C, et al. HLA DQB1*0301 allele is involved in the susceptibility to erythema multiforme. J Invest Dermatol 1991;97(4):697-700
116. Profaizer T, Eckels D. HLA alleles and drug hypersensitivity reactions. Int J Immunogenet 2012;39(2):99-105
117. de Roux Serratrice C, Serratrice J, Granel B, et al. [Stevens-Johnson syndrome followed by Gougerot-Sjogren syndrome]. Presse Med 2001;30(11):531-2
118. Foedinger D, Anhalt GJ, Boecskoer B, et al. Autoantibodies to desmoplakin I and II in patients with erythema multiforme. J Exp Med 1995;181(1):169-79
119. Hinterhuber G, Binder M, Marquardt Y, et al. Enzyme-linked immunosorbent assay for detection of peptide-specific human antidesmoplakin autoantibodies. Br J Dermatol 2005;153(2):413-16
120. Cozzani E, Di Zenzo G, Calabresi V, et al. Anti-desmoplakin antibodies in erythema multiforme and Stevens-Johnson syndrome sera: pathogenic or epiphenomenon? Eur J Dermatol 2011;21(1):32-6
121. Johnson SM, Smoller BR, Horn TD. Erythema multiforme associated human autoantibodies against desmoplakin I and II. J Invest Dermatol 1999;112(3):395-6
122. Washio K, Nakamura A, Fukuda S, et al. A case of lichen planus pemphigoides successfully treated with a combination of cyclosporine a and prednisolone. Case Rep Dermatol 2013;5(1):84-7
123. Zaraa I, Mahfoudh A, Sellami MK, et al. Lichen planus pemphigoides: four new cases and a review of the literature. Int J Dermatol 2013;52(4):406-12
124. Mignogna MD, Fortuna G, Leuci S, et al. Lichen planus pemphigoides, a possible example of epitope spreading. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;109(6):837-43
125. Lee HY, Blazek C, Beltraminelli H, Borradori L. Oral mucous membrane pemphigoid: complete response to topical tacrolimus. Acta Derm Venereol 2011; 91(5):604-5
126. Hamada T, Fujimoto W, Okazaki F, et al. Lichen planus pemphigoides and multiple keratoacanthomas associated with colon adenocarcinoma. Br J Dermatol 2004; 151(1):252-4
127. Stoebner PE, Michot C, Ligeron C, et al. [Simvastatin-induced lichen planus pemphigoides]. Ann Dermatol Venereol 2003;130(2 Pt 1):187-90
128. Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 2007;21(1):17-24
129. Maoz KB, Brenner S. Lichen planus pemphigoides triggered by narrowband UVB, paracetamol, and ibuprofen, with autoantibodies to 130kDa antigen. Skinmed 2008;7(1):33-6
130. Cohen DM, Ben-Amitai D, Feinmesser M, Zvulunov A. Childhood lichen planus pemphigoides: a case report and review of the literature. Pediatr Dermatol 2009;26(5): 569-74
131. Tamada Y, Yokochi K, Nitta Y, et al. Lichen planus pemphigoides: identification of 180 kd hemidesmosome antigen. J Am Acad Dermatol 1995;32(5 Pt 2):883-7
132. Sapadin AN, Phelps RG, Fellner MJ, Kantor I. Lichen planus pemphigoides presenting with a strikingly unilateral distribution. Int J Dermatol 1998;37(12): 942-6
133. Yoon KH, Kim SC, Kang DS, Lee IJ. Lichen planus pemphigoides with circulating autoantibodies against 200 and 180 kDa epidermal antigens. Eur J Dermatol 2000; 10(3):212-14
134. Zillikens D, Caux F, Mascaro JM, et al. Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180. J Invest Dermatol 1999;113(1): 117-21
135. Barnadas MA, Roe E, Dalmau J, et al. Lichen planus pemphigoides: detection of anti-BP 180 antibodies by ELISA and immunoblotting tests. J Eur Acad Dermatol Venereol 2010;24(11):1360-1
136. Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis 2010;69(8):1420-2
137. Dutz JP. T-cell-mediated injury to keratinocytes: insights from animal models of the lichenoid tissue reaction. J Invest Dermatol 2009;129(2):309-14
138. Fan W, Liang D, Tang Y, et al. Identification of microRNA-31 as a novel regulator contributing to impaired interleukin-2 production in T cells from patients with systemic lupus erythematosus. Arthritis Rheum 2012;64(11):3715-25
139. Gassling V, Hampe J, Acil Y, et al. Disease-associated miRNA-mRNA networks in oral lichen planus. PLoS One 2013;8(5): e63015